Current News & Events

April 29, 2008 – Zerusa Limited to attend EuroPCR 2008 course in Barcelona, Spain from May 13 - 16, 2008

Zerusa Limited, Galway, Ireland, announced today that the Company will attend the EuroPCR Congress for worldwide cardiologists, which will be held for the second straight year in Barcelona, Spain May 13 - 16, 2008.  The Company will focus on their innovative Guardian® hemostasis valve, which is gaining excellent physician aceptance in the interventional cardiology community.  Please come and visit the company's display, which will be incorporated into the larger Enterprise Ireland "Med in Ireland" booth at exhibit number G10. 

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

 

November 10 , 2007 – Zerusa Limited attends the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC, USA October 20 - 25, 2007

Chief Executive Officer, Ger Brett, commented, "The TCT is the premier annual gathering of interventional cardiologists from around the world. We would like to thank our US distribution partner, Vascular Solutions, Inc, for prominently displaying the Guardian at their booth. The Guardian received excellent physician exposure due to its use within several live case broadcasts from the New York Presbyterian/Columbia Medical Center in New York City. In one case, Paul Teirstein, MD, Chief of Cardiology and Director of Coronary Interventions at Scripps Clinic in LaJolla, California, spoke about the Guardian's clinical benefits during its use in complex cases involving multiple guidewires or catheters. Due to the Guardian's use in live cases, there was an increase in physician interest at the Vascular Solutions booth. The TCT was another solid milestone for Zerusa."

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises for the diagnosis and treatment of vascular disease.

About Vascular Solutions

Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within interventional radiology and interventional cardiology. The company’s five main product categories consist of hemostat (blood clotting) products, extraction catheters, vein products, specialty catheters and access products. New products introduced since the second half of 2003 include the D-Stat Dry™ hemostatic bandage for the rapid control of topical bleeding, the Pronto™ extraction catheter for the aspiration of soft thrombus, the Langston¬ dual lumen specialty catheter for the measurement of aortic stenosis, the Vari-Lase¬ endovenous laser product line for the treatment of varicose veins, and the Twin-Pass¬ dual access specialty catheter for dual wire access in interventional procedures.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2006 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to www.vascularsolutions.com.

Safe Harbors Statement

This press release contains forward-looking statements. Zerusa Limited wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Zerusa Limited’s overall business strategy, and other factors described in Zerusa Limited’s filings with the United States Securities and Exchange Commission.

Contact: Gerard Brett
Phone Number: +353-91-863061

September 5 , 2007 – Upcoming fall medical meetings

Come see the new, innovative Guardian hemostasis valve at the medical meetings listed below.  The Guardian will be on display at the booth of our US distribution partner, Vascular Solutions, Inc:

  • New Cardiovascular Horizons, New Orleans, LA; September 5-8; newcvhorizons.com
  • Capital Cardiovascular Conference, Harrisburg, PA; September 9-12;c32006
  • Scripps Coronary Interventions, San Diego, CA; October 3-5; CMEGME
  • New York ACE Meeting, NYC; October 6-10; www.ny-ace.com
  • Transcatheter Cardiovascular Therapeutics (TCT), Washington, DC;          October 20-25 (exhibit dates are October 22-24); www.tct2007.com